Pancreatic Cancer Drugs: Market Research Report

Date: April 22, 2010
Pages: 405
US$ 3,450.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Pancreatic Cancer Drugs: Market Research Report
This report analyzes the Global market for Pancreatic Cancer Drugs in US$ Million.

Annual forecasts are provided for the period 2006 through 2015.

The report profiles 57 companies including Abraxis BioScience, Inc., Amgen, Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd.., Genentech Inc., and OSI Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study



Current & Future Analysis
High Unmet Need and Challenges Abound, But Hope Persists
A Difficult to Diagnose and Treat Cancer
At Odds with Life After Pancreatic Cancer
Combination Therapies – A Potential Contender for Treatment
Clinical Research – In Search of Breakthrough Therapy
Active Pancreatic Cancer Pipeline – A Ray of Hope!
Targeted Therapy – The Promise, The Potential!
Research and Development – A Tough, Uphill Journey
Clinical Trials Failure Flickers The Hope for Pancreatic Cancer Treatment
Gemcitabine Fixation Mars Pancreatic Cancer Research
Competitive Landscape
Select Approved Drugs for Metastatic Pancreatic Cancer
United States - A Regional Overview
Pancreatic Cancer - Incidence and Mortality

Table 1. The American Cancer Society’s 5-year Relative Survival Rate for Patients with Pancreatic Cancer by Disease Stage

Poor Prognosis, Late Diagnosis and High Unmet Needs – The Challenges
The Funding Face Off
United Kingdom - A Regional Overview
Pancreatic Cancer – Brits Patients Fighting for Survival


Pancreas – The Vital Body Organ
Pancreatic Cancer – The Devastating Disease
Risk Factors of the Disease
Prevention of the Disease
Symptoms of the Disease
Diagnosis of the Disease
Abdominal Ultrasound
CT Scan
Percutaneous Biopsy
Endoscopic Biopsy
Treatment of the Disease
Surgical Treatment
Therapeutic Treatment
Treatment with Chemotherapy Drugs
Gemcitabine (Gemzar)

Table 2. Gemzar Sales by Region: 2007 and 2008 (USD Million)

Fluorouracil (5-FU)
Capecitabine (Xeloda)
Treatment with Targeted Drug Therapy
Erlotinib (Tarceva)

Table 3. Tarceva Pancreatic Cancer Sales Worldwide: 2007-2012 (includes corresponding Graph/Chart)

Treatment with Radiation Therapy
Other Therapies


Pfizer Announces Encouraging Results of Sutent, Stops Trial Ahead of Schedule
Abraxis BioScience Announces Interim Phase II Data for Abraxane
Concordia Announces Phase I/II Trial Results of Pancreatic Cancer Drug
Infinity Pharma Announces Preclinical Data of IPI-926
Celsion and Philips Complete Feasibility Stage, Commence Preclinical Development
Mayo Clinic Reports Encouraging Test Results of a New Drug Combination
Sidney Kimmel Researchers Report Positive Tigatuzumab Plus Gemcitabine Results
NCI Scientists Discover New Approach to Treat Pancreatic Cancer
Jefferson Researchers Report Potential of Herbal Extract in Pancreatic Cancer
American and Indian Scientists Discover New Pancreatic Cancer Therapy
Cambridge Scientists Discover Cause of Drug Failure in Pancreatic Cancer
CytRx Corp. Announces Trial Results of INNO-206
Amgen’s AMG 479 Shows Potential for Pancreatic Cancer Treatment
BioCancell Receives FDA Approval for BC-819 Phase I/II Trials
Rexahn Secures FDA Approval Phase II Trial of Archexin in Pancreatic Cancer
NeoPharm Files Application for Phase II Trial of LE-DT
Regeneron and Sanofi-aventis Terminate Phase III Study of Aflibercept
Pfizer Terminates Phase III Clinical Study of Axitinib
SciClone Terminates Phase II Trial of Pancreatic Cancer Drug
MediGene Announces Final Results of Phase II EndoTAG-1 Study
Abraxis BioScience Announces Positive Phase I Trial Results
Immunomedics Announces Development of Novel Antibody-Drug Conjugates
Roche’s Study Shows Avastin Plus Tarceva to Benefit Pancreatic Cancer Patients
Morphotek Inaugurates Additional Phase II Study Sites in EU
Pharmexa Announces Disappointing Data on GV1001, Terminates Study
Oncoscience to Commence New Phase IIb/IIIa Trial for Nimotuzumab
Bristol-Myers and ImClone Announce Disappointing Phase III Results of Erbitux


Roche Acquires Genentech
Sanofi-aventis Signs Agreement to Take Over BiPar Sciences
Cell Genesys and BioSante Complete Merger
Agennix and GPC Biotech Announce Merger
YM BioSciences Plans Merger with Cytopia
Myriad Acquires License to PALB2 Pancreatic Cancer Gene Patents
Seattle Genetics, Agensys Expand ADC Collaboration
Clavis Pharma Announces Agreement with Clovis Oncology for Anti-cancer Drug
GlobeImmune Enters into Strategic Global Oncology Alliance with Celgene
Rexahn and Teva Close Agreements for New Anti-cancer Agent, RX-3117
Taiho Pharma Announces Termination of S-1 Agreement with Sanofi-aventis
Cancer Advances to Raise Funds for Pancreatic Cancer Drug Trial
MacroChem Announces Virium Pharmaceuticals Acquisition
DARA BioSciences and Point Therapeutics Merge
GeneSense and Zor Sign Exclusive License Agreement for Virulizin
Cobra and ViroMed Ink Agreement for Anti-cancer Drug Development
GenVec and Cobra Ink Manufacturing Agreement
ARIUS Research and Laureate Pharma Ink Agreement for Trop-2


Chugai Submits Application for Additional Indication of Pancreatic Cancer
MediGene Secures FDA’s Orphan Drug Designation for Anti-cancer Candidate
Antisense Announces FDA and EMEA Orphan Drug Designation for Trabedersen
Clavis Announces EMEA’s Orphan Drug Recommendation for CP-4126
Epeius Receives FDA’s Fast Track Designation for Rexin-G
Abraxis BioScience Receives FDA’s Orphan Drug Status for Abraxane
Immunomedics Announces Fast Track Designation of FDA for hPAM4
Oncotherapy Science Plans Filing for Approval of Pancreatic Cancer Vaccine
GenVec Announces FDA’s Fast Track Designation for TNFerade
PharmaEngine Receives FDA’s Approval for PEP02 IND Application
Reata Receives FDA’s Orphan Drug Status for Anti-cancer drug, RTA 402
Marshall Edwards Announces FDA Orphan Drug Designation for Triphendiol
Tau Receive FDA’s Orphan Drug Status for Pancreatic Cancer Treatment
Regulon Receives Orphan Designation for Pancreatic Cancer Candidate, Cisplatin
Roche Wins European Approval for Tarceva


Abraxis BioScience, Inc. (USA)
Amgen, Inc. (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genentech Inc. (USA)
OSI Pharmaceuticals, Inc. (USA)


Table 4. World Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)


Total Companies Profiled: 57 (including Divisions/Subsidiaries - 61)
The United States
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middel East
Skip to top

Cancer Pancreatic Cancer Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 426 pages
Pancreatic Cancer Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 403 pages
Blood Cancer Drug Discoveries: what the future holds US$ 2,265.00 Apr, 2008 · 245 pages
Liver Cancer Drugs: Market Research Report US$ 3,950.00 Apr, 2010 · 506 pages

Ask Your Question

Pancreatic Cancer Drugs: Market Research Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: